Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Conditions: Metastatic Colorectal Cancer; Microsatellite Stable Colorectal Carcinoma; RAS Mutation; Cadonilimab Interventions: Drug: Cadonilimab + bevacizumab + FOLFOX Sponsors: Fudan University Recruiting

https://clinicaltrials.gov/study/NCT06218810

Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials